Synageva’s platform for protein production, processing, and purification will be used.

Morphotek entered a research agreement with Synageva BioPharma to express and develop therapeutic mAbs for the treatment of various cancers and infectious diseases. The Synageva Expression Platform (SEP™), which is an integrated technology for protein production, processing, and purification, will be used.

Morphotek’s pipeline includes MORAb-003, or farletuzumab, for ovarian cancer in Phase III, MORAb-009 for pancreatic cancer in Phase II, and MORAb-004 in Phase I trials in solid tumors. “We are always exploring new ways that may enhance the manufacturing process for our antibody products,” states Philip M. Sass, Ph.D., evp and COO, Morphotek.

Morphotek develops optimized antibodies for therapeutic applications and high-titer manufacturing cell lines using Morphodoma®. The antibodies within the company’s pipeline are targeted against antigens licensed from its collaborative partners.

Previous articleBioSante to Take Over Cell Genesys in a $38M All-Stock Deal
Next articleInvestigators Identify SNPs Associated with Predisposition to Schizophrenia